| Sign In to gain access to subscriptions and/or personal tools. |
The use of transdermal fentanyl in pediatric oncology palliative careHaematology and Oncology Unit, Royal Children’s Hospital, Brisbane, Queensland, Australia
Haematology and Oncology Unit, Royal Children’s Hospital, Brisbane, Queensland, Australia Transdermal fentanyl offers a noninvasive approach to the management of patients with opioid dependent and stable, chronic cancer pain. The transdermal delivery system offers distinct advantages where oral administration of opioids is difficult as a consequence of progressive disease and in patients whose compliance with oral medications is poor. Thirteen patients ranging in age from three years and nine months to 18 years and seven months were treated with transdermal fentanyl for between six hours and 112 days. All had previously been receiving oral morphine prior to the commencement of fentanyl and were transferred to fentanyl because of oral opioid side effects and poor oral compliance. Fentanyl was well tolerated and provided effective pain relief for 11 of 13 patients. Overall, patients and parents experienced satisfaction with fentanyl, both in terms of pain relief and improvement in quality of life.
Key Words: advanced cancer • cancer pain • opioids • palliative care • pediatric oncology • symptom management • transdermal fentanyl
American Journal of Hospice and Palliative Medicine®, Vol. 18, No. 6,
411-416 (2001) This article has been cited by other articles:
|
|||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
